Search Share Prices
Tissue Regenix begins sales of 'DermaPure' from CellRight Texas facility
(WebFG News) - Regenerative medical devices company Tissue Regenix Group announced on Tuesday that, following the successful completion of the manufacturing technical transfer, it has begun sales of 'DermaPure' products processed at the CellRight Technologies facility in San Antonio, Texas.
The AIM-traded firm said the completion of the transfer of DermaPure, ahead of schedule, would bring a number of benefits to the group, including the expansion of manufacturing capabilities to meet increasing demands from global sales and distribution partners.
It would also improve supply chain production efficiency, and product life cycle management, with process enhancements increasing DermaPure's shelf life from two to three years, and in-house manufacturing facilitating the augmentation of the product portfolio, Tissue Regenix's board explained.
Commercialised under the recently rebranded TRX BioSurgery division, it said DermaPure was being utilised in an increased number of clinical applications, including acute and chronic wound care, orthopaedic trauma, dental, and following the exclusive distribution agreement with ARMS medical, urogynaecology and urology.
"We are extremely encouraged by the continued progress integrating CellRight into the Tissue Regenix Group," said CEO Steve Couldwell.
"Completing the transfer of DermaPure manufacturing to our CellRight facility was achieved, ahead of schedule, and incorporated significant process improvements which is a testament to the CellRight team."
Couldwell said the move was an "important strategic milestone" in the group's long-term commercial strategy, and he was "pleased" that the operational synergies were developing as expected.
"As a result we now have greater flexibility to explore new product opportunities to meet patient demand, expanding the markets we operate in with a reduced manufacturing risk profile."